1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population

Background: On March 11, 2020 World Health Organization (WHO) declared the global pandemic for Sars-Cov-2 Virus (COVID-19) Patients with cancer are generally more vulnerable to infections, systematic studies of diverse cohorts of patients with cancer affected by COVID-19 are needed Methods: Retrospective study of patients hospitalized with PCR+ for COVID-19 to assess the rate of cancer patients and describe clinical, pathological characteristics and evolution of their disease In addition, a transversal study of seroprevalence (IgG/IgM by ELISA-method) against Sars-Cov-2 is being carried out in patients undergoing active treatment Immunophenotype analysis will be performed for patients with IgG/IgM+ test and a cohort of patients with negative test that will be used as controls Results: 581 patients with mild to severe COVID-19 and PCR+ have been admitted at the Arnau Vilanova University Hospital in Valencia, Spain A total of 18 patients had medical history of cancer (3%) 72% were male and median age was 76 years Most frequent cancers were breast (16,7%), colon (16,7%) and bladder (16,7%) Fourteen had been treated for an early stage and were disease free at the time of the COVID-19 (83,3%) Three patients were on active systemic therapy: 2 chemotherapy (1 on neoadjuvant treatment for bladder cancer, 1 on chemo-radiotherapy for stage III NSCLC, and 1 with adjuvant Imatinib for GIST) One patient with advanced hepatocarcinoma was on palliative treatment Most frequent symptoms were dyspnoea (66,7%), cough (66,7%), fever (66,7%), asthenia (44,4%) and diarrhea (16,7%) Four patients (22,2%) required Intensive Care and six (33,3%) died Preliminary results of first 86 ambulatory patients on active treatment evaluated for seroprevalence against Sars-Cov-2 reveal a 0% of IgG or IgM antibodies Conclusions: Rate of cancer patients admitted in hospital with COVID-19 infection was 3% Cancer patients are more likely to be elderly and present comorbidities that increase COVID-19 infection risk, so whether cancer might be a risk factor itself remains controversial We plan to recruit 300 patients on oncologic treatment, our preliminary results show a 0% seroprevalence Final results will be communicated at ESMO meeting Legal entity responsible for the study: Javier Garde-Noguera Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest